Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

Astrazeneca,U.s.,Headquarters,In,Wilmington,,De,,Usa,,November,5,,2023.

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

MG is a chronic autoimmune disorder that causes muscle weakness and fatigue. The disease is characterized by antibodies against the acetylcholine receptor, a protein found on the surface of nerve cells that plays a key role in muscle contraction.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.